TABLE 1.
Features set 1 (20 features) | Measure | Features set 2,a n (%) | Measure | Features set 3,b n (%) | Measure |
---|---|---|---|---|---|
Age, yc | 49 (41–58) | Histologic condition | Beta-blocker use | ||
Race/ethnicity, n (%) | Squamous cell | 578 (75.3) | No | 710 (92.9) | |
White | 64 (8.3) | Adenocarcinoma | 137 (17.8) | Yes | 54 (7.1) |
Black | 48 (6.3) | Adenosquamous | 31 (4.0) | Primary hysterectomy | |
Hispanic | 551 (71.7) | Other | 22 (2.9) | No | 559 (72.8) |
Asian | 101 (13.2) | Stage | Yes | 209 (27.2) | |
Others | 4 (0.5) | I | 372 (48.7) | Radiotherapy | |
Body mass index, kg/m2c,d | 28.0 (24.3–32.8) | IA1 | 91 (11.8) | No | 297 (38.7) |
Hypertension, n (%)e | IA2 | 21 (2.7) | Yes | 471 (61.3) | |
No | 569 (74.5) | IB1 | 160 (20.8) | Chemotherapy | |
Yes | 195 (25.5) | IB2 | 100 (13.0) | No | 699 (91.0) |
Diabetes mellitus, n (%)e | II | 167 (21.9) | Yes | 69 (9.0) | |
No | 654 (85.6) | IIA | 30 (3.9) | ||
Yes | 110 (14.4) | IIB | 136 (17.7) | ||
Hypercholesterolemia, n (%)e | II NOS | 1 (0.1) | |||
No | 701 (91.8) | III | 156 (20.4) | ||
Yes | 63 (8.2) | IIIA | 7 (0.9) | ||
Vital signs at diagnosisc | IIB | 149 (19.4) | |||
Systolic blood pressure, mm Hg | 125 (112–140) | IV | 69 (9.0) | ||
Diastolic blood pressure, mm Hg | 72 (65–80) | IVA | 11 (1.4) | ||
Heart rate, beats/min | 79 (70–89) | IVB | 58 (7.6) | ||
Laboratory testc | Unknown | 4 (0.5) | |||
White blood cell, ×109/L | 8.3 (6.6–10.0) | ||||
Platelet, ×109/L | 300 (244–451) | ||||
Hemoglobin, g/dL | 12.3 (10.2–13.4) | ||||
Blood urea nitrogen, mg/dL | 12.0 (9.0–15.0) | ||||
Creatinine, mg/dL | 0.6 (0.5–0.8) | ||||
Bicarbonate, mEq/L | 25 (23–27) | ||||
Albumin, g/dL | 4.1 (3.7–4.4) |
Included the demographics for features set 1 and the 16 listed tumor features
Included the demographics for features set 1, the 16 tumor features for features set 2, and the listed treatment features
Data are given as median (interquartile range)
Missing 20 data
Missing 4 data.